pyrazines has been researched along with Fatty Liver, Nonalcoholic in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexopoulos, SJ; Chen, SY; Childress, ES; Dai, Y; Garcia, CJ; Hargett, SR; Hoehn, KL; Salamoun, JM; Santiago-Rivera, J; Santos, WL; Shah, DP; Tucker, SP | 1 |
| Alexopoulos, SJ; Beretta, M; Chen, SY; Garcia, CJ; Hargett, SR; Hoehn, KL; Murray, JH; Olzomer, EM; Salamoun, JM; Santos, WL; Shah, DP; Tucker, SP | 1 |
| Goto, N; Hirano, H; Ichikawa, T; Ino, Y; Inoue, R; Kimura, Y; Kyohara, M; Li, J; Miyashita, D; Ohnuma, H; Okuyama, T; Shirakawa, J; Tajima, K; Takayanagi, R; Terauchi, Y; Togashi, Y; Vethe, H; Yamasaki, S | 1 |
| Lin, J; Wang, SY | 1 |
| Kim, W; Kim, YJ | 1 |
| Chen, B; Hu, G; Lin, Y; Ma, Y; Wei, J; Xue, X | 1 |
| Akaslan, SB; Arslan, M; Cakir, N; Degertekin, CK; Toruner, FB; Yilmaz, G | 1 |
| Anand, S; Bhatia, T; Olaywi, M; Singhal, S | 1 |
| Chang, MS; Cho, JY; Kim, BG; Kim, H; Kim, JH; Kim, SG; Kim, W; Kim, YJ; Lee, CK; Lee, J; Lee, JH; Lee, JS; Yeon, JE; Yi, S | 1 |
| Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H | 1 |
1 review(s) available for pyrazines and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review.
Topics: Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fatty Liver; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Liver; Non-alcoholic Fatty Liver Disease; Peptides; Pyrazines; Sitagliptin Phosphate; Transaminases; Treatment Outcome; Triazoles; Venoms | 2013 |
1 trial(s) available for pyrazines and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.
Topics: Adult; Animals; Double-Blind Method; Fatty Liver; Female; Humans; Liver X Receptors; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Mice; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes; Treatment Outcome; Ultrasonography | 2017 |
8 other study(ies) available for pyrazines and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
[1,2,5]Oxadiazolo[3,4-
Topics: Animals; Diamines; Liver; Male; Mice, Inbred C57BL; Mitochondria, Liver; Non-alcoholic Fatty Liver Disease; Oxadiazoles; Oxygen Consumption; Pyrazines; Uncoupling Agents | 2020 |
6-Amino[1,2,5]oxadiazolo[3,4-
Topics: Alanine Transaminase; Aniline Compounds; Animals; Cell Line; Diet, High-Fat; Disease Models, Animal; Half-Life; Liver; Mice; Mitochondria; Myoblasts; Non-alcoholic Fatty Liver Disease; Oxygen Consumption; Pyrazines; Rats; Structure-Activity Relationship; Triglycerides; Uncoupling Protein 1 | 2020 |
Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Blood Glucose; Cytochrome P450 Family 2; Gene Expression Regulation; Hepatocytes; Imidazoles; Insulin; Intercellular Signaling Peptides and Proteins; Linagliptin; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Perilipin-2; Pyrazines; Receptor, IGF Type 1; Receptor, Insulin; Steroid Hydroxylases; Triglycerides | 2020 |
Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed.
Topics: Fatty Liver; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes | 2017 |
Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed-authors' reply.
Topics: Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes | 2017 |
Tetramethylpyrazine reduces inflammation in the livers of mice fed a high fat diet.
Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Biopsy; Blood Glucose; Cytokines; Diet, High-Fat; Disease Models, Animal; Female; Hepatitis; Inflammation Mediators; Male; Mice; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pyrazines; Reactive Oxygen Species | 2019 |
Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.
Topics: Alanine Transaminase; Animals; Blood Glucose; Cholesterol; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Female; Insulin; Insulin Resistance; Liver; Non-alcoholic Fatty Liver Disease; Obesity; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles; Triglycerides | 2013 |
The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
Topics: Adult; Alanine Transaminase; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Drug Evaluation; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Inflammation; Liraglutide; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Odds Ratio; Pioglitazone; Platelet Count; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2012 |